KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study - Cohen, EEW; Soulières, D; Le Tourneau, C (Lancet, 2019)
et al.